Odyssey Therapeutics

BOSTON, MA · Founded 2021 · CIK 0001882782 · Biotech · Private

Small molecule therapeutics for autoimmune and inflammatory diseases

odysseytx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$571M
4 Form D · Dec 2025
10 months since last filing
Contracts
—
No federal contracts on record
Patents
40
1 granted · 39 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$91,629,837
Private capital raisedForm D · SEC$168,009,933
Private capital raisedForm D · SEC$97,130,000
Private capital raisedForm D · SEC$214,025,200
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1124Kriya Therapeutics—$769M
1125VERSATOPE THERAPEUTICS, INC.——
1126Inhibrx, Inc.—$669M
1127Odyssey Therapeutics—$571M
1128Moderna—$556M
1129Mariana Oncology——
1130OMVAX, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 19 related persons
  • Charles BaumDirector
  • Chuck BaumDirector
  • M. BaumDirector
  • Jill CarrollDirector
  • Shelley ChuDirector
  • Gary GlickDirector · Executive Officer
  • Carl GordonDirector
  • Jason HaasExecutive Officer
  • Paulina HillDirector
  • Lorence KimDirector
  • Jeffrey LeidenDirector
  • Nan LiDirector
  • Carolyn NgDirector
  • Valerie OdegardDirector
  • Ksenija PavleticDirector
  • Ian SmithDirector
  • lan SmithDirector
  • Nia TatsisDirector
  • Timothy WalbertDirector

Patents

USPTO · 1 granted of 40
  • Inhibitors Of RIPK2 And Medical Uses Thereofapplication
  • Inhibitors Of RIPK2 And Medical Uses Thereofapplication
  • Inhibitors Of RIPK2 And Medical Uses Thereofgranted
  • ANTI-TNFR2 Antigen-binding Proteins And Uses Thereofapplication
  • Multispecific Molecules Binding TNFR2 And CD25 And Uses Thereofapplication
  • ANTI-CD25 Antigen-binding Proteins And Uses Thereofapplication
  • Anti-thymic Stromal Lymphopoietin (tslp) Antigen-binding Proteins And Uses Thereofapplication
  • Antigen-binding Proteins Against Serum Albumin And Uses Thereofapplication
  • Inhibitors Of RIPK2 And Uses Thereofapplication
  • Crystalline Forms Of RIPK2 Inhibitorapplication
  • Multispecific Molecules Binding TRAILR2 And CDH17 And Uses Thereofapplication
  • Multispecific Molecules Binding TRAILR2 And CDH17 And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.